1. Home
  2. ANL vs FRMI Comparison

ANL vs FRMI Comparison

Compare ANL & FRMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

SELL

Current Price

$10.00

Market Cap

998.8M

Sector

N/A

ML Signal

SELL

Logo Fermi Inc.

FRMI

Fermi Inc.

SELL

Current Price

$2.40

Market Cap

1.0B

Sector

Real Estate

ML Signal

SELL

Company Overview

Basic Information
Metric
ANL
FRMI
Founded
2004
2025
Country
Singapore
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Sector
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
998.8M
1.0B
IPO Year
2022
2025

Fundamental Metrics

Financial Performance
Metric
ANL
FRMI
Price
$10.00
$2.40
Analyst Decision
Strong Buy
Buy
Analyst Count
7
9
Target Price
★ $29.50
$15.63
AVG Volume (30 Days)
229.1K
★ 24.7M
Earning Date
08-14-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$243.83
N/A
Revenue Next Year
N/A
$1,486.49
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$1.44
52 Week High
$17.25
$19.22

Technical Indicators

Market Signals
Indicator
ANL
FRMI
Relative Strength Index (RSI) 41.78 45.80
Support Level $8.95 N/A
Resistance Level $11.75 $7.65
Average True Range (ATR) 1.03 0.37
MACD 0.20 0.11
Stochastic Oscillator 42.35 58.99

Price Performance

Historical Comparison
ANL
FRMI

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

About FRMI Fermi Inc.

Fermi Inc develops next-generation private electric grids that deliver redundant power at gigawatt scale to support next-generation intelligence and AI compute. It combines cutting-edge technology with a deep bench of world-class, multidisciplinary leaders with a combined 25 GW of experience to create one of the world's 17 GW next-gen private grids, helping ensure America's energy and AI dominance. The behind-the-meter Project Matador campus is expected to integrate the nation's combined-cycle natural gas project, one of the clean, new nuclear power complexes in America, utility grid power, solar power, and battery energy storage, to support hyperscale AI and computing.

Share on Social Networks: